-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $21

Benzinga·11/13/2026 18:33:59
Listen to the news
BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $21.